Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
1/2상
완료
NCT03410030
| 대상 질환 | Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma |
|---|
| 임상 단계 | 1/2상 |
|---|
| 스폰서 | HonorHealth Research Institute |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 17 명 |
|---|
| 중재(약물) | High Dose Ascorbic Acid 25 g/m^2, Nanoparticle Paclitaxel protein bound 125mg/m^2, Cisplatin 25mg/m^2, Gemcitabine 1000mg/m^2, High Dose Ascorbic Acid 37.5 g/m^2 |
|---|
| 시작일 | 2017년 12월 15일 |
|---|
| 완료일 | 2021년 9월 14일 |
|---|
| 결과 공개일 | 2026년 7월 23일 |
|---|
요약
The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer.
Total Dose Received [Identifying Recommended Maximum Tolerated Dose (MTD)]
From enrollment through end of treatment, up to 40 weeks · Dose (g/m^2)
| Ascorbic Acid 25 g/m^2 | 235.3 ± 66.3 Dose (g/m^2) |
|---|
| Ascorbic Acid 37.5 g/m^2 | 410.4 ± 62.0 Dose (g/m^2) |
|---|
| Ascorbic Acid 56.25 g/m^2 | 589.1 ± 135.7 Dose (g/m^2) |
|---|
Duration of Dose in Days [Identifying Recommended Maximum Tolerated Dose (MTD)]
From enrollment through end of treatment, up to 40 weeks · Days
| Ascorbic Acid 25 g/m^2 | 235.5 ± 51.9 Days |
|---|
| Ascorbic Acid 37.5 g/m^2 | 165.9 ± 51.4 Days |
|---|
| Ascorbic Acid 56.25 g/m^2 | 149.0 ± 54.2 Days |
|---|
Duration of Dose in Weeks [Identifying Recommended Maximum Tolerated Dose (MTD)]
From enrollment through end of treatment, up to 40 weeks · Weeks
| Ascorbic Acid 25 g/m^2 | 33.6 ± 7.4 Weeks |
|---|
| Ascorbic Acid 37.5 g/m^2 | 23.7 ± 7.3 Weeks |
|---|
| Ascorbic Acid 56.25 g/m^2 | 21.3 ± 7.7 Weeks |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.